TherapeuticsMD Statistics
Total Valuation
TherapeuticsMD has a market cap or net worth of $14.12 million. The enterprise value is $15.35 million.
Important Dates
The next estimated earnings date is Monday, August 11, 2025, after market close.
| Earnings Date | Aug 11, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
TherapeuticsMD has 11.57 million shares outstanding. The number of shares has increased by 5.99% in one year.
| Current Share Class | 11.57M |
| Shares Outstanding | 11.57M |
| Shares Change (YoY) | +5.99% |
| Shares Change (QoQ) | +0.17% |
| Owned by Insiders (%) | 1.61% |
| Owned by Institutions (%) | 13.11% |
| Float | 9.56M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 7.39 |
| Forward PS | n/a |
| PB Ratio | 0.51 |
| P/TBV Ratio | 0.62 |
| P/FCF Ratio | 10.04 |
| P/OCF Ratio | 10.04 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 8.34 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 10.91 |
Financial Position
The company has a current ratio of 2.64, with a Debt / Equity ratio of 0.26.
| Current Ratio | 2.64 |
| Quick Ratio | 1.84 |
| Debt / Equity | 0.26 |
| Debt / EBITDA | n/a |
| Debt / FCF | 4.95 |
| Interest Coverage | -1,566.50 |
Financial Efficiency
Return on equity (ROE) is -7.72% and return on invested capital (ROIC) is -5.58%.
| Return on Equity (ROE) | -7.72% |
| Return on Assets (ROA) | -4.88% |
| Return on Invested Capital (ROIC) | -5.58% |
| Return on Capital Employed (ROCE) | -9.35% |
| Revenue Per Employee | $1.84M |
| Profits Per Employee | -$2.10M |
| Employee Count | 1 |
| Asset Turnover | 0.05 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -63,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -32.60% in the last 52 weeks. The beta is 0.64, so TherapeuticsMD's price volatility has been lower than the market average.
| Beta (5Y) | 0.64 |
| 52-Week Price Change | -32.60% |
| 50-Day Moving Average | 1.27 |
| 200-Day Moving Average | 1.25 |
| Relative Strength Index (RSI) | 47.95 |
| Average Volume (20 Days) | 68,863 |
Short Selling Information
The latest short interest is 83,865, so 0.72% of the outstanding shares have been sold short.
| Short Interest | 83,865 |
| Short Previous Month | 90,601 |
| Short % of Shares Out | 0.72% |
| Short % of Float | 0.88% |
| Short Ratio (days to cover) | 2.16 |
Income Statement
In the last 12 months, TherapeuticsMD had revenue of $1.84 million and -$2.10 million in losses. Loss per share was -$0.19.
| Revenue | 1.84M |
| Gross Profit | 1.84M |
| Operating Income | -3.13M |
| Pretax Income | -6.13M |
| Net Income | -2.10M |
| EBITDA | -2.66M |
| EBIT | -3.13M |
| Loss Per Share | -$0.19 |
Full Income StatementBalance Sheet
The company has $5.75 million in cash and $6.97 million in debt, giving a net cash position of -$1.23 million or -$0.11 per share.
| Cash & Cash Equivalents | 5.75M |
| Total Debt | 6.97M |
| Net Cash | -1.23M |
| Net Cash Per Share | -$0.11 |
| Equity (Book Value) | 26.74M |
| Book Value Per Share | 2.31 |
| Working Capital | 7.77M |
Full Balance SheetCash Flow
| Operating Cash Flow | 1.41M |
| Capital Expenditures | n/a |
| Free Cash Flow | 1.41M |
| FCF Per Share | $0.12 |
Full Cash Flow StatementMargins
Gross margin is 100.00%, with operating and profit margins of -170.18% and -114.07%.
| Gross Margin | 100.00% |
| Operating Margin | -170.18% |
| Pretax Margin | -119.61% |
| Profit Margin | -114.07% |
| EBITDA Margin | -144.60% |
| EBIT Margin | -170.18% |
| FCF Margin | 76.43% |
Dividends & Yields
TherapeuticsMD does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.99% |
| Shareholder Yield | -5.99% |
| Earnings Yield | -14.87% |
| FCF Yield | 9.96% |
Dividend DetailsAnalyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 9, 2022. It was a reverse split with a ratio of 0.02:1.
| Last Split Date | May 9, 2022 |
| Split Type | Reverse |
| Split Ratio | 0.02:1 |
Scores
TherapeuticsMD has an Altman Z-Score of -33.92 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -33.92 |
| Piotroski F-Score | 4 |
